News | Oncology Diagnostics | October 30, 2017

Laser Scanner Detects Skin Cancer in Less Than 30 Seconds

A team of European scientists has developed the world’s first cancer scanner that detects blood vessels grown by a malignant melanoma with an infrared laser beam in 30 seconds

Laser Scanner Detects Skin Cancer in Less Than 30 Seconds

Image courtesy of VivoSight

cancer detection scanning patient

Image courtesy of VivoSight

 Photonics VivoSightDX OCT cancer detection screen

Image courtesy of VivoSight

October 30, 2017 — Current skin cancer diagnosis can last a number of weeks and be very upsetting. However, a new imaging system developed by a group of European scientists could dramatically speed up the process and reduce the need for debilitating sentinel-lymph node biopsies by placing real-time cancer diagnosis in the hands of a dermatologist.

Multiple stages of skin cancer diagnosis can involve visiting a GP, being sent to a dermatologist for a skin biopsy, waiting for laboratory analysis, having a sentinel lymph node biopsy under general anaesthetic, and then having more tests if the cancer has spread.

Now, using a handheld laser, a specialist can actually see under the skin at depths of 1 mm by creating a 3-D color image of the microscopic blood vessels in a process that takes around 30 seconds.

Employing a new and advanced version of optical coherence tomography (OCT), a photonics technique more commonly used in retina scans, the scanner captures 3-D images of the micro-structures under the skin with a harmless infrared laser beam.

Since melanomas need oxygen to grow and survive, they grow their own blood vessels. As the cancer develops and becomes more malignant, they become increasingly distorted and malformed, differing in appearance from healthy vessels.

Being able to detect and see these vessels in a suspicious lesion in real time has never been possible, until now, opening the possibility for dermatologists to make treatment decisions in an unrivalled timeframe.

Over 55,500 people in the world died from malignant melanoma of the skin in 2012 alone. While 2,459 deaths from melanoma skin cancer were recorded in the United Kingdom in 2014, an estimated 9,730 people will die of melanoma in the United States in 2017.

Melanomas produce their own blood vessels to feed and grow the tumor, so by revealing the microstructures in 3-D pictures the scanner show doctors how the cancer has developed.

A specialist can potentially determine on the spot, whether simply cutting it out is sufficient for a cure or whether further treatment with cancer drugs will be needed.

With their new device called VivoSight on the market, the European team ADVANCE (Automatic Detection of VAscular Networks for Cancer Evaluation) is aiming to reduce the time for treatment decision from a number of weeks to a matter of seconds, while removing the invasive nature of the appointment.

U.K. project leader Jon Holmes of Michelson Diagnostics Ltd, a key partner in the ADVANCE consortium, explained, “Every melanoma above a certain thickness could have spread to other parts of the body. At present, all patients with such melanomas have to wait for a sentinel lymph node biopsy performed in a hospital under general anesthesia to find out if it is spreading. This can take weeks to perform, is very expensive and can be debilitating for the patient.”

The ADVANCE team has employed a variant of OCT in its scanner called speckle-variance OCT or dynamic OCT (D-OCT), an advancement of OCT that is ideal for capturing movement.

Studying the ‘speckle’ or flicker of light patterns created by moving blood cells, the imaging device takes around four frames per second and compiles the images so that a clinician may tell where something has moved on the image from frame to frame.

“Using D-OCT we can see movement of blood against the solid tissue structures, something we have never been able to do before in a clinical setting. It’s like looking out at night and seeing cars’ headlights flowing along a motorway, only at depths of nanometers under the skin,” said Holmes.

While a sentinel node biopsy can cost in excess of €10,000 (~$13,000 U.S.), and with many hospitals performing hundreds per year, there is a growing concern and a need to find an alternative when over 80 percent of these operations turn out to be clear of any malignant growth, according to Holmes.

As well as its use in skin cancer diagnosis, the ability to see blood vessel networks with the ADVANCE technology has created a number of useful spin-off benefits.

“The scanner can image the blood vessels in healing wounds. This may have application for treatment of leg and foot chronic ulcers, when doctors want to know whether a wound is healing or requires a change in treatment, potentially reducing the number of amputations,” said Holmes. He added,

“ADVANCE technology may also help with burn victims, being able to give a doctor a quicker response time than the standard 15 days to determine whether a patient’s skin is healing and whether or not to give a skin graft.”

For more information: www.photonics21.org

Related Content

Smoldering Spots in the Brain May Signal Severe MS

NIH researchers found that dark rimmed spots representing ongoing, “smoldering” inflammation, may be a hallmark of more disabling forms of multiple sclerosis. Image courtesy of Reich lab, NIH/NINDS.

News | Neuro Imaging | August 22, 2019
Aided by a high-powered brain scanner and a 3-D printer, National Institutes of Health (NIH) researchers peered inside...
Improved Imaging Technique Could Increase Chances of Prostate Cancer Survival
News | Prostate Cancer | August 20, 2019
According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their...
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
RSNA and ACR to Collaborate on Landmark Medical 3D Printing Registry
News | Medical 3-D Printing | August 08, 2019
The Radiological Society of North America (RSNA) and the American College of Radiology (ACR) will launch a new medical...
Synaptive Medical Launches Modus Plan With Automated Tractography Segmentation
Technology | Neuro Imaging | August 07, 2019
Synaptive Medical announced the U.S. launch and availability of Modus Plan featuring BrightMatter AutoSeg. This release...
Rise in Early Onset Colorectal Cancer Not Aligned With Screening Trends
News | Colonoscopy Systems | August 06, 2019
A new study finds that trends in colonoscopy rates did not fully align with the increase in colorectal cancer (CRC) in...
Volpara to Distribute Screenpoint Medical's Transpara AI Solution
News | Breast Imaging | August 02, 2019
Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint's Transpara...
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...